Response to: Comment on the implications of external price referencing of pharmaceuticals in Middle East countries

Zoltán Kaló; Zoltán Vokó; Kasem S Akhras; Panos Kanavos

doi:10.1586/14737167.2016.1136792

Response to: Comment on the implications of external price referencing of pharmaceuticals in Middle East countries

Expert Rev Pharmacoecon Outcomes Res. 2016;16(1):15-6. doi: 10.1586/14737167.2016.1136792.

Authors

Zoltán Kaló^{1

2}, Zoltán Vokó^{1

2}, Kasem S Akhras³, Panos Kanavos⁴

Affiliations

¹ a Syreon Research Institute , Budapest , Hungary.
² c Department of Health Policy and Health Economics , Eötvös Loránd University , Budapest , Hungary.
³ b Novartis Pharma Services AG , Dubai , UAE.
⁴ d Department of Social Policy , London School of Economics , London , UK.

PMID: 26707267
DOI: 10.1586/14737167.2016.1136792

No abstract available

Keywords: Cross-national price comparison; Middle East countries; external reference pricing; pharmaceutical pricing; price corridor for pharmaceuticals.

Publication types

Letter
Comment

MeSH terms

Commerce / economics*
Drug Costs / statistics & numerical data*
Humans
Pharmaceutical Preparations / economics*

Substances

Pharmaceutical Preparations